{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:03:13Z","timestamp":1785416593683,"version":"3.56.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clear Cell Renal cell carcinoma (ccRCC) is the most common form of kidney cancer. The VHL tumor suppressor is lost or mutated in the majority of ccRCC and hereditary mutations in VHL predispose patients to ccRCC. However, another tumor suppressor, RASSF1A is inactivated at even higher levels in ccRCC. The majority of ccRCC lose function of both proteins. This suggests there may be some functional link between them. We found that the RASSF1A and VHL proteins can form a complex, suggesting they may act in concert to suppress the tumorigenic phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated two matched sets of Renal cancer tumor cell systems where we added back or knocked down both genes.  We also made compound transgenic mice with induced, dual inactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the add-back system we found that the proteins cooperated to suppress 3D cell growth and sensitized cells to apoptosis inducing agents. In the knockdown system, we found the double loss cooperated to promote growth in 3D. In cell line xenografts, we found that the loss of VHL alone was insufficient to promote tumorigenesis, but it acted as an accelerant on tumor growth by RASSF1A deficient cells, which showed enhanced vascularization differential deregulation of HIF1\u03b1 compared to HIF2\u03b1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first report of an interaction between RASSF1A and VHL and may explain why RASSF1A is so frequently inactivated in Renal cancer. However, further studies in transgenic mice showed that dual inactivation of the tumor suppressors did not result in the formation of tumors or macrocysts. Thus, additional genetic lesions are likely required for the development of ccRCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1884868","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:32:25Z","timestamp":1785414745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Howard","family":"Donninger","sequence":"first","affiliation":[{"name":"Brown Cancer Center, Department of Medicine, University of Louisville","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Ferrill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Louisville","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hobbing","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Louisville","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Vos","sequence":"additional","affiliation":[{"name":"National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey J.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Louisville","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/op.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105070","article-title":"VHL mutation drives human clear cell renal cell carcinoma progression through PI3K\/AKT-dependent cholesteryl ester accumulation","volume":"103","author":"Zhang","year":"2024","journal-title":"EBioMedicine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-1865","article-title":"The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/medsci12010012","article-title":"Hereditary renal cancer syndromes","volume":"12","author":"Yanus","year":"2024","journal-title":"Med Sci (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041316","article-title":"Downstream targets of VHL\/HIF-alpha signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance","volume":"15","author":"Mazumder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.04.011","article-title":"Von-Hippel Lindau and hypoxia-inducible factor at the center of renal cell carcinoma biology","volume":"37","author":"Shirole","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2024.151386","article-title":"Regulation of the HIF switch in human endothelial and cancer cells","volume":"103","author":"Slawski","year":"2024","journal-title":"Eur J Cell Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-4142","article-title":"The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion","volume":"71","author":"Koh","year":"2011","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3689","article-title":"Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (review)","volume":"12","author":"Yang","year":"2015","journal-title":"Mol Med Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.08.165","article-title":"The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing","volume":"338","author":"Kaelin","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0491","article-title":"The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma","volume":"19","author":"Choueiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2017.1301680","article-title":"HIF-1 in cancer therapy: two decade long story of a transcription factor","volume":"56","author":"Soni","year":"2017","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01106-y","article-title":"Targeting HIF-2 alpha in renal cell carcinoma","volume":"24","author":"Ahmed","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217318","article-title":"The role of hypoxia-inducible factor-1 alpha in renal disease","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.010389","article-title":"The RASSF1A tumor suppressor","volume":"120","author":"Donninger","year":"2007","journal-title":"J Cell Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.2.3.16286","article-title":"RASSF1A: Not a prototypical Ras effector","volume":"2","author":"Gordon","year":"2011","journal-title":"Small GTPases"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-49","article-title":"RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis","volume":"6","author":"Peters","year":"2007","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-0339","article-title":"A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability","volume":"64","author":"Vos","year":"2004","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00202-14","article-title":"The RASSF1A tumor suppressor regulates XPA-mediated DNA repair","volume":"35","author":"Donninger","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"307628","DOI":"10.1155\/2012\/307628","article-title":"Hippo and rassf1a pathways: a growing affair","volume":"2012","author":"Fausti","year":"2012","journal-title":"Mol Biol Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m512128200","article-title":"The RASSF1A tumor suppressor activates Bax via MOAP-1","volume":"281","author":"Vos","year":"2006","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.02011-07","article-title":"Dynamics of RASSF1A\/MOAP-1 association with death receptors","volume":"28","author":"Foley","year":"2008","journal-title":"Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1038\/s41467-019-10044-z","article-title":"A RASSF1A-HIF1alpha loop drives Warburg effect in cancer and pulmonary hypertension","volume":"10","author":"Dabral","year":"2019","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.12.003","article-title":"Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma","volume":"107","author":"Catalano","year":"2025","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.142193799","article-title":"Rig is a novel Ras-related protein and potential neural tumor suppressor","volume":"99","author":"Ellis","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m114.594283","article-title":"Ras regulates SCF-beta-TrCP activity and specificity via its effector NORE1A","volume":"289","author":"Schmidt","year":"2014","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat Med"},{"key":"B32","first-page":"395","article-title":"Biological assays for Ras transformation","volume-title":"Methods in Enzymology","author":"Clark","year":"1995"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-3241","article-title":"Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor","volume":"66","author":"Rankin","year":"2006","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.92.65.1","article-title":"Tumor susceptibility of Rassf1a knockout mice","volume":"65","author":"Tommasi","year":"2005","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131216298","article-title":"The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis","volume":"98","author":"Dreijerink","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21769\/bioprotoc.2351","article-title":"Soft agar colony formation assay as a hallmark of carcinogenesis","volume":"7","author":"Du","year":"2017","journal-title":"Bio Protoc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2010.02.008","article-title":"Ras-association domain family member 1A (RASSF1A)-where the heart and cancer meet","volume":"19","author":"Oceandy","year":"2009","journal-title":"Trends Cardiovasc Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41419-019-2169-x","article-title":"RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review","volume":"10","author":"Dubois","year":"2019","journal-title":"Cell Death Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.21203\/rs.3.rs-846239\/v1","article-title":"Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1044-579x(02)00103-7","article-title":"The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis","volume":"13","author":"Pugh","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J Neuroimmune Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.218396","article-title":"CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease","volume":"107","author":"Kim","year":"2010","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13185","article-title":"Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases","volume":"117","author":"Kalra","year":"2016","journal-title":"BJU Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234034","article-title":"The current state of the diagnoses and treatments for clear cell renal cell carcinoma","volume":"16","author":"Quinn","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00876-w","article-title":"Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma","volume":"21","author":"Liao","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci162480","article-title":"Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2091-8-s1-s4","article-title":"Role of the ubiquitin proteasome system in renal cell carcinoma","author":"Corn","year":"2007","journal-title":"BMC Biochem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-328-3:167","article-title":"VHL and kidney cancer","volume":"222","author":"Ohh","year":"2003","journal-title":"Methods Mol Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13287-023-03528-9","article-title":"HIF-1alpha promotes kidney organoid vascularization and applications in disease modeling","volume":"14","author":"Peng","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000363669","article-title":"Role of hypoxia-inducible factors in acute kidney injury","volume":"127","author":"Andringa","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1083\/jcb.201006059","article-title":"Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability","volume":"190","author":"Thoma","year":"2010","journal-title":"J Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00756.x","article-title":"Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells","volume":"99","author":"Chuang","year":"2008","journal-title":"Cancer Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/onc.2010.440","article-title":"Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy","volume":"30","author":"Tommasi","year":"2011","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03786-1","article-title":"p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics","volume":"147","author":"Diesing","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/fon-2023-0679","article-title":"Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond","author":"Curry","year":"2024","journal-title":"Future Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1038\/s41598-025-34381-w","article-title":"Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors","volume":"16","author":"Rowe","year":"2026","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m511408200","article-title":"Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways","volume":"281","author":"Elvidge","year":"2006","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.107","article-title":"Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis","volume":"24","author":"Monzon","year":"2011","journal-title":"Mod Pathol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1alpha and HIF-2alpha differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1884868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:32:27Z","timestamp":1785414747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1884868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":59,"alternative-id":["10.3389\/fonc.2026.1884868"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1884868","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1884868"}}